- Home
- SHMD vs CRVS Comparison
SHMD vs CRVS Comparison
Compare SHMD & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHMD
- CRVS
- Stock Information
- Founded
- SHMD 1864
- CRVS 2014
- Country
- SHMD Germany
- CRVS United States
- Employees
- SHMD N/A
- CRVS N/A
- Industry
- SHMD
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- SHMD
- CRVS Health Care
- Exchange
- SHMD Nasdaq
- CRVS Nasdaq
- Market Cap
- SHMD 144.3M
- CRVS 516.0M
- IPO Year
- SHMD N/A
- CRVS 2016
- Fundamental
- Price
- SHMD $2.58
- CRVS $5.10
- Analyst Decision
- SHMD
- CRVS Strong Buy
- Analyst Count
- SHMD 0
- CRVS 5
- Target Price
- SHMD N/A
- CRVS $12.38
- AVG Volume (30 Days)
- SHMD 51.8K
- CRVS 1.7M
- Earning Date
- SHMD 02-25-2025
- CRVS 11-12-2024
- Dividend Yield
- SHMD N/A
- CRVS N/A
- EPS Growth
- SHMD 1309.32
- CRVS N/A
- EPS
- SHMD 1.07
- CRVS N/A
- Revenue
- SHMD $99,752,404.00
- CRVS N/A
- Revenue This Year
- SHMD N/A
- CRVS N/A
- Revenue Next Year
- SHMD N/A
- CRVS N/A
- P/E Ratio
- SHMD $2.30
- CRVS N/A
- Revenue Growth
- SHMD N/A
- CRVS N/A
- 52 Week Low
- SHMD $1.98
- CRVS $1.30
- 52 Week High
- SHMD $6.13
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- SHMD N/A
- CRVS 36.16
- Support Level
- SHMD N/A
- CRVS $4.93
- Resistance Level
- SHMD N/A
- CRVS $6.47
- Average True Range (ATR)
- SHMD 0.00
- CRVS 0.40
- MACD
- SHMD 0.00
- CRVS 0.06
- Stochastic Oscillator
- SHMD 0.00
- CRVS 29.74
About SHMD SCHMID Group N.V. Class A Ordinary Shares
Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).